Caris Life Sciences (CAI) Profit After Tax (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Profit After Tax of -$510000.0 for Q1 2026, up 99.5% year-over-year from -$255635.7 in Q1 2025, and down 100.62% quarter-over-quarter from $82.0 million in Q4 2025.
Caris Life Sciences (CAI) Profit After Tax (2024 - 2026) Analysis & Trends
Caris Life Sciences' Profit After Tax history runs 3 years deep, the most recent figure standing at -$510000.0 for Q1 2026.
- In Q1 2026, Profit After Tax rose 99.5% year-over-year to -$510000.0; the TTM figure through Mar 2026 stood at -$411.4 million (down 50.46% YoY), while the FY2025 annual figure was -$68.1 million, up 75.85% from the prior year.
- Profit After Tax for Q1 2026 stood at -$510000.0, down from $82.0 million in the prior quarter.
- The five-year high for Profit After Tax was $82.0 million in Q4 2025, with the low at -$517.2 million in Q2 2025.
- The 3-year median for Profit After Tax is -$51.5 million (2024), against an average of -$85.6 million.
- Peak annual rise in Profit After Tax reached 321.78% in 2025, while the deepest fall reached 682.52% in 2025.
- Caris Life Sciences' Profit After Tax stood at -$37.0 million in 2024, then jumped by 321.78% to $82.0 million in 2025, then plunged by 100.62% to -$510000.0 in 2026.
- Business Quant data shows CAI's Profit After Tax at -$510000.0 in Q1 2026, $82.0 million in Q4 2025, and $24.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | -1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.00 Mn |
| Mar 31, 2026 | -510,000.00 |
| Dec 31, 2025 | 81.96 Mn |
| Sep 30, 2025 | 24.33 Mn |
| Jun 30, 2025 | -517.20 Mn |
| Mar 31, 2025 | -102.55 Mn |
| Dec 31, 2024 | -36.96 Mn |
| Sep 30, 2024 | -67.85 Mn |
| Jun 30, 2024 | -66.09 Mn |